(Press-News.org) Alzheimer’s Disease (AD), the leading cause of dementia, affects nearly 40 million individuals globally, resulting in a gradual loss of memory and independence. Despite extensive research over the past decades, no treatments have been found that can halt or reverse the progression of this devastating disease.
In AD, a major contributor to neuronal dysfunction is the protein tau. Tau typically plays a crucial role in keeping the internal structure of neurons stable, much like train tracks help trains stay on course. However, in some diseases, tau undergoes abnormal modifications and starts to aggregate, disrupting this transport system, thus leading to neuronal damage and subsequent memory loss.
An international team of researchers has reported a new mechanism by which boosting the natural metabolite NAD⁺ can protect the brain from the degeneration associated with AD. Their paper, titled “NAD⁺ reverses Alzheimer’s neurological deficits via regulating differential alternative RNA splicing of EVA1C”, is published in the renowned journal Science Advances.
The team is led by Associate Professor Evandro Fei Fang from the University of Oslo and Akershus University Hospital, Norway, in collaboration with Professor Oscar Junhong Luo from Jinan University, China, and Associate Professor Joana M. Silva from the University of Minho, Portugal.
How NAD⁺ supports brain health
NAD⁺ (Nicotinamide adenine dinucleotide, oxidised form) is a vital metabolite involved in energy metabolism and neuronal resilience in the body. It is normally declined with age and especially in various neurodegenerative diseases. “Preliminary studies have shown that supplementation with NAD⁺ precursors, such as nicotinamide riboside (NR) or nicotinamide mononucleotide (NMN), can offer therapeutic benefits in AD animal models and early clinical trials. However, the molecular mechanisms behind these benefits remain largely unclear”, first author Alice Ruixue Ai, says.
The new study reveals that NAD⁺ works through a previously unidentified RNA-splicing pathway. This pathway is regulated by a protein called EVA1C, which plays an essential role in the process of RNA splicing. RNA splicing allows a single gene to produce multiple isoforms of a protein, and one isoform may show distinctive effects to the other isoforms. Its dysregulation is one of the most recently acknowledged risk factor for AD.
The researchers discovered that when NAD⁺ levels are increased, EVA1C helps correct mistakes in RNA splicing. This restoration process improves the function of hundreds of genes, many crucial for brain health, which can help reverse the neurodegenerative damage caused by tau.
Cross-species validation from worms to mice to the human brain
To demonstrate the impact of this mechanism, the researchers used a comprehensive approach that included computer predictions and validation in different animal models, including worms, mice, as well as human brain samples.
They first identified age-related changes in RNA splicing in a specific type of worm. They found that adding NAD⁺ could correct the splicing issues caused by the toxic tau protein. In mice with tau-related mutations, NAD⁺ supplements improved RNA splicing, restored brain function, and enhanced memory performance. “Notably, we found when the EVA1C gene was knocked down, these benefits were lost, confirming that EVA1C is essential for NAD⁺-mediated neuroprotection”, Associate Professor Evandro Fei Fang-Stavem says.
Aligned with these animal studies, EVA1C levels was significantly reduced in brain cells from people with early AD.
Using AI to uncover the mechanism
To further investigate how EVA1C works, the team used an AI-driven platform to predict how proteins interact with one another, analysing structural, sequential, and evolutionary data from millions of proteins. This analysis revealed that NAD⁺ promotes a specific form of EVA1C that efficiently binds to essential proteins, which are central to protein folding and clearance. This connection links metabolic homeostasis, RNA splicing processes and protein management, three processes that are critically impaired in AD.
Towards new Alzheimer’s treatments
By establishing the connection between NAD⁺ and EVA1C, this study lays the groundwork for the development of new therapies and optimization of NAD⁺ augmentation strategies in humans. “We propose that maintaining NAD⁺ levels could help preserve neuronal identity and delay cognitive decline, paving the way for combination treatments to enhance RNA splicing”, Ai says.
International collaboration
The study underscores the power of international collaboration in tackling complex brain diseases by involving partners from Norway, China, Portugal, the UK, Japan, Greece, and Spain. The four co-first authors are (Alice) Ruixue Ai (UiO/Ahus, Norway), Lipeng Mao (JNU, China), Xurui Jin (MindRank AI, China), and C. Campos-Marques (UMinho, Portugal).
----
For additional information
Evandro Fei Fang (Evandro Fei Fang-Stavem,方飛), Ph.D, Associate Professor, Department of Clinical Molecular Biology, University of Oslo and Akershus University Hospital, 1478 Lørenskog, Norway; The Norwegian Centre on Healthy Ageing (NO-Age) and The Norwegian National Anti-Alzheimer’s Disease (NO-AD) Networks, Oslo 0372, Norway.
Email: e.f.fang@medisin.uio.no Website: https://evandrofanglab.com/
Oscar Junhong Luo, Ph.D, Professor, Department of Oncology, The First Affiliated Hospital, Jian University, Guangzhou 510632, China; Guangdong-Hong Kong-Macau Great Bay Area Geroscience Joint Laboratory, 510632 Guangzhou, China
Email: luojh@jnu.edu.cn Website: https://jnumed.jnu.edu.cn/xtswyxx/list.htm
Joana Margarida Silva, Ph.D, Associate Professor, Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Campus Gualtar, 4710-057 Braga, Portugal; ICVS/3B’s - PT Government Associate Laboratory, Braga/Guimarães, Portugal
Email: joanamsilva@med.uminho.pt Website: https://icvs.uminho.pt/member/joana-margarida-silva/?utm_source=chatgpt.com
END
You are having dinner with friends, and the conversation is lively. Do your hands join the chat, or do they stay focused on your knife and fork?
New research from Duke’s Department of Psychology & Neuroscience shows that gesture is not merely a matter of individual style or habit, but a reflection of cultural expression tied to racial identity.
The research also suggests that mismatched expectations about gesture may influence the dynamics of interracial communication.
“The biggest takeaway is we all clearly communicate in very different ways,” said Gaither, Nicholas J. and Theresa M. Leonardy Associate Professor ...
When scientists compared what California sea lions eat in the Channel Islands (U.S.) and the Gulf of California (Mexico), they expected to find a clear explanation for why populations were booming in California but shrinking in Mexico. Instead, they found something more complicated.
The study found that what sea lions eat may matter less than where they live. Despite large regional differences in population trends, the study found that the overall energy value of sea lion diets in the Gulf of California ...
SAN ANTONIO, Nov. 10, 2025 – A simple blood test for platelet activity at middle age could one day help identify people at risk for Alzheimer’s disease decades ahead of time, allowing for possible preventive therapy.
The blood-clotting process in vascular dysfunction is linked to key markers of Alzheimer’s as early as midlife, a study co-led by researchers at The Glenn Biggs Institute for Alzheimer’s and Neurodegenerative Diseases at UT Health San Antonio, the academic health center of The University of Texas at San Antonio, and the New York University Grossman School of Medicine shows.
Vascular dysfunction refers to a condition ...
Research Highlights:
A one-month course of dual clot-preventing therapy followed by a single clot-prevention medication for the remainder of the standard 12-month regimen in adults with atrial fibrillation (AFib) who received a coronary stent was as effective as one year of continuous dual therapy for preventing stroke, heart attack and death.
Participants treated with the one-month regimen experienced fewer bleeding problems than those in the year-long dual-treatment group.
This is the first study to suggest the one-month strategy is as safe and effective as the standard year-long regimen of dual clot-preventing therapy for people with AFib treated with a stent.
Note: ...
Research Highlights:
Successful catheter ablation resulted in a low risk of stroke associated with atrial fibrillation (AFib), a type of irregular heart rhythm, according to an international study.
Researchers said these findings may suggest that ongoing blood-thinning medication may not be needed after an ablation procedure.
While catheter ablation is known to reduce the occurrence of AFib, it’s been unclear if it also reduces the increased stroke risk associated with the AFib.
Note: This ...
Research Highlights:
Earlier blood transfusion after major surgery – when hemoglobin was below 10 g/dL rather than beow 7 g/dl - did not affect the risk of severe complications, such as death, heart attack, need for a heart procedure, kidney failure or stroke.
However, the timing of the blood transfusion may be associated with a lower risk of irregular heartbeat and heart failure among people with heart disease, according to a new study of U.S. military veterans.
Note: This trial is simultaneously published today as a full manuscript in the peer-reviewed scientific journal JAMA.
Embargoed ...
Texas Tech University researchers have received grant funding totaling roughly $12.25 million over five years from the National Science Foundation (NSF) to explore infrastructure necessary for large-scale computing that uses multiple energy sources.
The REmotely-managed Power-Aware Computing Systems and Services (REPACSS) project will build an advanced system prototype and develop and test tools for automation, remote data control, and scientific workflow management.
REPACSS will be housed at the ...
Research Highlights:
Adults with atrial fibrillation and obesity/overweight (but no diabetes) who took the diabetes medication metformin after a rhythm correction procedure were more likely to stay free of AFib episodes for a year.
Weight loss was not thought to be the main reason metformin helped, since there was only a modest weight change among those taking the medication.
Future studies may compare the impact of metformin with other diabetes medications in treating adults with obesity and AFib.
Note: The study featured in this news release is a research abstract. Abstracts presented at American Heart Association’s scientific meetings are not ...
DALLAS, Nov. 10, 2025 — Despite major advances in care, nearly half of U.S. adults live with some form of cardiovascular disease or stroke, according to the American Heart Association®, a relentless force changing the future of health for everyone everywhere. To close this gap, innovative health solutions must reach people where they live, work and play. At its Scientific Sessions 2025, the Association recognized two pioneering companies whose health technologies could help do just that.
Houston-based PolyVascular was named the overall winner of the American Heart Association’s annual Health Tech Competition, earning top honors in the business category. ...
Research Highlights:
During the 6 months after treatment to restore a normal heart rhythm, adults with atrial fibrillation (AFib) who were randomly assigned to drink coffee every day were 39% less likely to have a recurrence of AFib compared to participants assigned to not have any coffee or other caffeinated drinks.
The results of the 200-person trial may challenge the common belief that caffeine may spur more abnormal heart rhythms such as AFib.
Researchers say it is reasonable for health care professionals to let their AFib patients try naturally caffeinated drinks ...
